About Us

AgeneBio is dedicated to developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.

Our mission is to discover and develop innovative therapeutics that preserve and restore brain function for patients at risk for neurodegeneration, to benefit the lives of those patients, their families, and society as a whole.

Our pipeline of novel therapies includes multiple candidates to treat patients with neurological and psychiatric disease and is based on decades of research focused on cognitive neuroscience and the neurobiology of the aging brain. Our most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. With this candidate, we believe we will deliver the first and only therapeutic to target hippocampal overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia.

AGB101

Our Phase 3-ready asset is intended to treat aMCI and delay progression to Alzheimer’s dementia. We plan to initiate our Phase 3 HOPE4MCI trial in 2017.

Discovery: GABAA α5 positive allosteric modulators

Our novel late-stage discovery program offers therapeutic potential for a spectrum of untreated conditions including aMCI, autism and schizophrenia. We expect to submit an Investigational New Drug (IND) application in the first half of 2017.

agenebio-development-timeline